Status:
COMPLETED
Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Laboratorio Progenetica
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lu...
Eligibility Criteria
Inclusion
- Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIB-IV)
- Tumour sample (block of slides) available for KRAS analysis
Exclusion
- Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by cytology, with no tumour sample access.
- Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00956280
Start Date
September 1 2009
End Date
April 1 2010
Last Update
May 13 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Belo Horizonte, Brazil
2
Research Site
Porto Alegre, Brazil
3
Research Site
Rio de Janeiro, Brazil
4
Research Site
Santo André, Brazil